Journal Information
Vol. 21. Issue 5.
(May 2025)
Share
Download PDF
More article options
Vol. 21. Issue 5.
(May 2025)
Original Article
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry
Tasa de retención a un año de ixekizumab en pacientes con artritis psoriásica y espondiloartritis axial: datos de vida real del registro BIOBADASER
Clementina López-Medinaa,
Corresponding author
clementinalopezmedina@gmail.com

Corresponding author.
, Lucía Otero-Varelab, Fernando Sánchez-Alonsob, Vega Jovaníc, Lorena Expósito-Pérezd, Sheila Melchor-Díaze, Yanira Pérez-Veraf, Paula Pretel-Ruizg, Javier Maneroh, Antonio Mera-Varelai, Lourdes Mateoj, Dolores Ruiz-Montesinok, José Andrés Lorenzo-Martínl, Teresa Pedraz-Penalvam, Isabel Castrejónn,o
a University of Cordoba, Reina Sofia University Hospital, IMIBIC, Cordoba, Spain
b Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
c Hospital General Universitario de Alicante Dr. Balmis, ISABIAL, Alicante, Spain
d Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
e Hospital Universitario 12 de Octubre, Madrid, Spain
f Hospital Universitario de Gran Canarias Dr. Negrín, Las Palmas de Gran Canaria, Spain
g Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
h Hospital Universitario Miguel Servet, Zaragoza, Spain
i Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
j Hospital Universitario Germans Trias I Pujol, Badalona, Spain
k Hospital Universitario Virgen Macarena, Sevilla, Spain
l Hospital Universitario de Burgos, Burgos, Spain
m Hospital General Universitario de Elda Virgen de la Salud, Elda, Spain
n Gregorio Marañón University Hospital, Madrid, Spain
o Faculty of Medicine, Complutense University, Madrid, Spain
Ver más
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Baseline characteristics of the overall population and per disease.
Tables
Table 2. Probability of retention after 12-months of treatment with IXE and reasons of discontinuation.
Tables
Table 3. Baseline factors independently associated with the withdrawal of IXE per disease.
Tables
Show moreShow less
Additional material (1)
Abstract
Introduction

Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.

Method

Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.

Results

A total of 335 patients ever exposed to IXE were included (PsA=250; axSpA=85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.

Conclusions

In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.

Keywords:
Psoriatic arthritis
Axial spondyloarthritis
Ixekizumab
Resumen
Introducción

Ixekizumab (IXE) es un anticuerpo monoclonal selectivo de la interleucina 17A (IL-17A) aprobado para el tratamiento de la artritis psoriásica (PsA) y la espondiloartritis axial (EspAax). Existen datos limitados de vida real sobre su tasa de retención y efectividad. El objetivo de este estudio fue evaluar la tasa de retención a un año de IXE en una cohorte de vida real de pacientes con EspAax y PsA, y determinar los posibles factores predictivos de la retención del fármaco.

Métodos

Estudio prospectivo y observacional derivado de BIOBADASER 3.0, un registro multicéntrico de terapias avanzadas que incluye a pacientes que alguna vez han recibido IXE para PsA o EspAax. La tasa de retención del tratamiento a un año en ambas enfermedades se evaluó utilizando curvas de Kaplan-Meier y regresiones de Cox multivariables.

Resultados

Se incluyeron un total de 335 pacientes que alguna vez estuvieron expuestos a IXE (PsA=250; EspAax=85). IXE se utilizó como tratamiento de primera línea solo en el 5,3% de los pacientes y, después de TNFi, en el 94,7% de los pacientes. En EspAax y PsA, la supervivencia del fármaco a los 12 meses fue del 69,5% (IC95%: 64,0-74,3), ligeramente mayor en PsA (71,3%; IC95%: 65,0-75,6) frente a EspAax (63,8%; IC95%: 51,5-73,7)). Los modelos de regresión de Cox multivariables mostraron que el sexo femenino y una mayor duración de la enfermedad fueron factores asociados con la interrupción de IXE en toda la población, mientras que el uso concomitante de metotrexato redujo el riesgo de interrupción.

Conclusiones

En este estudio del mundo real, IXE mostró una tasa de retención aceptable en pacientes con PsA y EspAax después de un año de seguimiento. El sexo femenino y una mayor duración de la enfermedad se asociaron con el riesgo de interrupción.

Palabras clave:
Artritis psoriásica
Espondiloartritis axial
Ixekizumab

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?